Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.83)
# 442
Out of 4,574 analysts
387
Total ratings
51.1%
Success rate
19.1%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterated: Buy | $95 | $34.79 | +173.07% | 24 | Jul 24, 2026 | |
| IVA Inventiva | Reiterated: Buy | $15 | $4.46 | +236.32% | 18 | Jul 20, 2026 | |
| EYPT EyePoint | Initiated Coverage: Buy | $40 | $12.19 | +228.14% | 1 | Jul 16, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $35.25 | $8.22 | +328.85% | 2 | Jul 10, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $255 → $332 | $300.53 | +10.47% | 8 | Jul 8, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $42 | $9.73 | +331.65% | 26 | Jun 25, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $250 | $138.01 | +81.15% | 9 | Jun 24, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $50 → $40 | $11.13 | +259.39% | 10 | Jun 1, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $50 → $56 | $62.00 | -9.68% | 10 | May 12, 2026 | |
| TRVI Trevi Therapeutics | Rated: Buy | $18 → $30 | $17.54 | +71.09% | 24 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $26.71 | +94.68% | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $230 | $253.87 | -9.40% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $55 | $46.20 | +19.05% | 31 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 | $5.98 | +184.28% | 26 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 | $49.12 | +83.22% | 8 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 | $11.44 | +144.76% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.77 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $0.8509 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2,160.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.51 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $7.03 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21.15 → $19.74 | $6.25 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.0082 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $3.00 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $2.06 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $10.09 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $6.63 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $95.36 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $5.53 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $33.36 | n/a | 1 | Oct 18, 2011 |
Viking Therapeutics
Jul 24, 2026
Reiterated: Buy
Price Target: $95
Current: $34.79
Upside: +173.07%
Inventiva
Jul 20, 2026
Reiterated: Buy
Price Target: $15
Current: $4.46
Upside: +236.32%
EyePoint
Jul 16, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $12.19
Upside: +228.14%
Eupraxia Pharmaceuticals Inc.
Jul 10, 2026
Reiterated: Buy
Price Target: $35.25
Current: $8.22
Upside: +328.85%
Ligand Pharmaceuticals
Jul 8, 2026
Reiterated: Buy
Price Target: $255 → $332
Current: $300.53
Upside: +10.47%
REGENXBIO
Jun 25, 2026
Reiterated: Buy
Price Target: $42
Current: $9.73
Upside: +331.65%
Palvella Therapeutics
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $138.01
Upside: +81.15%
Oculis Holding AG
Jun 1, 2026
Maintained: Buy
Price Target: $50 → $40
Current: $11.13
Upside: +259.39%
MBX Biosciences
May 12, 2026
Reiterated: Buy
Price Target: $50 → $56
Current: $62.00
Upside: -9.68%
Trevi Therapeutics
May 8, 2026
Rated: Buy
Price Target: $18 → $30
Current: $17.54
Upside: +71.09%
May 7, 2026
Maintained: Buy
Price Target: $52
Current: $26.71
Upside: +94.68%
May 6, 2026
Reiterated: Buy
Price Target: $230
Current: $253.87
Upside: -9.40%
May 6, 2026
Maintained: Hold
Price Target: $55
Current: $46.20
Upside: +19.05%
May 5, 2026
Maintained: Buy
Price Target: $17
Current: $5.98
Upside: +184.28%
Feb 27, 2026
Maintained: Buy
Price Target: $90
Current: $49.12
Upside: +83.22%
Jan 15, 2026
Maintained: Buy
Price Target: $28
Current: $11.44
Upside: +144.76%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.77
Upside: -
Apr 1, 2025
Maintained: Buy
Price Target: $8
Current: $0.8509
Upside: n/a
Jan 8, 2025
Maintained: Buy
Price Target: n/a
Current: $2,160.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $2.51
Upside: n/a
Aug 30, 2023
Maintained: Hold
Price Target: $11
Current: $7.03
Upside: n/a
Nov 3, 2022
Maintained: Buy
Price Target: $21.15 → $19.74
Current: $6.25
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.0082
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $3.00
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $5
Current: $2.06
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $10.09
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $6.63
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $95.36
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $5.53
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $33.36
Upside: n/a